129 related articles for article (PubMed ID: 38377623)
1. Thermoresponsive carboplatin-releasing prodrugs.
McAdam AD; Batchelor LK; Romano-deGea J; Vasilyev D; Dyson PJ
J Inorg Biochem; 2024 May; 254():112505. PubMed ID: 38377623
[TBL] [Abstract][Full Text] [Related]
2. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
3. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
Yao H; Chen S; Deng Z; Tse MK; Matsuda Y; Zhu G
Inorg Chem; 2020 Aug; 59(16):11823-11833. PubMed ID: 32799491
[TBL] [Abstract][Full Text] [Related]
4. [Effects of hyperthermia combined platinum-based drugs on ovarian cancer cell lines SKOV3].
Xie D; Yin RT; Li KM; Xiao P; Tong LX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):606-11. PubMed ID: 25286685
[TBL] [Abstract][Full Text] [Related]
5. Optimization of axial ligands to promote the photoactivation of BODIPY-conjugated platinum(IV) anticancer prodrugs.
Yao H; Gunawan YF; Liu G; Tse MK; Zhu G
Dalton Trans; 2021 Oct; 50(39):13737-13747. PubMed ID: 34519297
[TBL] [Abstract][Full Text] [Related]
6. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.
Varbanov HP; Valiahdi SM; Kowol CR; Jakupec MA; Galanski MS; Keppler BK
Dalton Trans; 2012 Dec; 41(47):14404-14415. PubMed ID: 22886297
[TBL] [Abstract][Full Text] [Related]
7. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Los G; Smals OA; van Vugt MJ; van der Vlist M; den Engelse L; McVie JG; Pinedo HM
Cancer Res; 1992 Mar; 52(5):1252-8. PubMed ID: 1737387
[TBL] [Abstract][Full Text] [Related]
8. Potent Chlorambucil-Platinum(IV) Prodrugs.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142383
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional Pt(iv) prodrug candidates featuring the carboplatin core and deferoxamine.
Harringer S; Hejl M; Enyedy ÉA; Jakupec MA; Galanski MS; Keppler BK; Dyson PJ; Varbanov HP
Dalton Trans; 2021 Jun; 50(23):8167-8178. PubMed ID: 34031671
[TBL] [Abstract][Full Text] [Related]
10. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
11. Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: synthesis, characterization, in vitro cytotoxicity studies and a comparative ab initio, and DFT studies with cisplatin, carboplatin, and oxaliplatin.
Alexander C; Nithyakumar A; Paul MWB; Arockia Samy N
J Biol Inorg Chem; 2018 Jul; 23(5):833-848. PubMed ID: 29934700
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.
Barth MC; Häfner N; Runnebaum IB; Weigand W
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982792
[TBL] [Abstract][Full Text] [Related]
13. Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology.
Formenti SC; Shrivastava PN; Sapozink M; Jozsef G; Chan KK; Jeffers S; Morrow PC; Muggia FM
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):993-1001. PubMed ID: 8751408
[TBL] [Abstract][Full Text] [Related]
14. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.
Johnstone TC; Suntharalingam K; Lippard SJ
Chem Rev; 2016 Mar; 116(5):3436-86. PubMed ID: 26865551
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo.
Kusumoto T; Holden SA; Ara G; Teicher BA
Int J Hyperthermia; 1995; 11(4):575-86. PubMed ID: 7594810
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin prodrug conjugated Fe
Song H; Quan F; Yu Z; Zheng M; Ma Y; Xiao H; Ding F
J Mater Chem B; 2019 Jan; 7(3):433-442. PubMed ID: 32254730
[TBL] [Abstract][Full Text] [Related]
17. The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs - an HPLC-ICP-MS study.
Theiner S; Grabarics M; Galvez L; Varbanov HP; Sommerfeld NS; Galanski MS; Keppler BK; Koellensperger G
Dalton Trans; 2018 Apr; 47(15):5252-5258. PubMed ID: 29560976
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, antiproliferative activity and estrogen receptor α affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues.
Saha P; Descôteaux C; Brasseur K; Fortin S; Leblanc V; Parent S; Asselin E; Bérubé G
Eur J Med Chem; 2012 Feb; 48():385-90. PubMed ID: 22209414
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of platinum analogue cytotoxicity by hyperthermia.
Xu MJ; Alberts DS
Cancer Chemother Pharmacol; 1988; 21(3):191-6. PubMed ID: 3282706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
